Skip to content

Released Nov 8, 2016

10-Q filed Nov 8, 2016, 39 days after period end · 0001232524-16-000384

Q3 2016 · 10-Q
Revenue$374.18M+9.8% vs Q3 2015−1.8% vs Q2 2016
Net Income$89.83M+2.1% vs Q3 2015−21.5% vs Q2 2016
EPS Diluted$1.45+4.3% vs Q3 2015−21.6% vs Q2 2016
Gross Profit$347,310,000+11.9%
Operating Income$136,253,000+3.6%
Operating Cash Flowderived$133,028,000−24.0%
Free Cash Flowderived$130,646,000−23.1%
Margins · derived
Gross margin92.8%+1.8 pt vs Q3 2015
Operating margin36.4%−2.2 pt vs Q3 2015
Net margin24.0%−1.8 pt vs Q3 2015

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ3 2016Q3 2015Q3 2014Q3 2013
Revenue$374.18M$340.87M$306.58M$232.16M
Net Income$89.83M$87.96M$25.77M$75.41M
EPS Diluted$1.45$1.39$0.41$1.23

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR